Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Lisbon H. Lundbeck A/S |
---|---|
Information provided by: | University of Lisbon |
ClinicalTrials.gov Identifier: | NCT00353665 |
The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the progression of Amyotrophic Lateral Sclerosis (ALS). Memantine is added to riluzole (the single drug approved to treat ALS).
Condition | Intervention | Phase |
---|---|---|
Amyotrophic Lateral Sclerosis |
Drug: Memantine (Ebixa) Drug: riluzole Drug: Placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis |
Enrollment: | 63 |
Study Start Date: | July 2005 |
Study Completion Date: | January 2009 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 - active: Experimental
memantine + riluzole
|
Drug: Memantine (Ebixa)
10 mg bid
Drug: riluzole
riluzole 50 mg bid
|
2: Placebo Comparator
riluzole + placebo
|
Drug: riluzole
riluzole 50 mg bid
Drug: Placebo
|
Phase 2/3 trial in ALS patients Double-blinded, parallel, randomized (2 blocs, bulbar/spinal onset)
Memantine + riluzole x Placebo + Memantine
Inclusion criteria:
Duration - 2 years
Evaluation - every 3 months
Primary outcome - ALS-FRS Secondary -SF36, Hamilton depression scale, motor unit number estimation, neurophysiological index, strength (clinical evaluation); side-effects
Intention to treat analysis
60 patients
number estimated for 50% change in decline rate of ALS-FRS
Ages Eligible for Study: | 20 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Portugal | |
Department of Neurology - Hospital de Santa Maria | |
Lisbon, Portugal, 1649-028 | |
Department of Neurology - Hospital de Santa Maria | |
Lisbon, Portugal, 1649-028 |
Principal Investigator: | Mamede de Carvalho, MD | Department of Neurology- Hospital de Santa Maria |
Responsible Party: | Instituto de Medicina Molecular ( Mamede de Carvalho ) |
Study ID Numbers: | 002-04 |
Study First Received: | July 18, 2006 |
Last Updated: | March 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00353665 History of Changes |
Health Authority: | Portugal: National Pharmacy and Medicines Institute |
amyotrophic lateral sclerosis motor neuron disease memantine clinical trial |
Riluzole Excitatory Amino Acids Neurotransmitter Agents Spinal Cord Diseases Central Nervous System Diseases Sclerosis Neurodegenerative Diseases Neuroprotective Agents Dopamine |
Neuromuscular Diseases Lou Gehrig's Disease Amyotrophic Lateral Sclerosis Memantine Dopamine Agents Motor Neuron Disease Degenerative Motor System Disease Anticonvulsants |
Neurotransmitter Agents Spinal Cord Diseases Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Antiparkinson Agents Excitatory Amino Acid Agents Neurodegenerative Diseases Neuroprotective Agents Pathologic Processes Neuromuscular Diseases Therapeutic Uses Memantine |
Motor Neuron Disease Excitatory Amino Acid Antagonists Riluzole Nervous System Diseases Central Nervous System Diseases Sclerosis Protective Agents Pharmacologic Actions Amyotrophic Lateral Sclerosis Dopamine Agents Central Nervous System Agents Anticonvulsants |